Low baseline neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict increased overall survival in locally recurrent rectal cancer despite R1 margins

Dig Liver Dis. 2022 Jul;54(7):864-870. doi: 10.1016/j.dld.2022.01.002. Epub 2022 Jan 31.

Abstract

Background: Prognostic features in locally recurrent rectal cancer (LRRC), beyond R0 surgery, are unknown.

Aims: Aim of the present study was to evaluate the prognostic role of peripheral immune estimators, such as neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), on survival outcomes in LRRC patients.

Methods: 184 LRRC patients treated at the National Cancer Institute of Milan (Italy) were included. Optimal cut-off values for NLR and PLR were determined. Kaplan-Meier curves and multivariate Cox analyses were used to assess the 5-yr overall survival (OS) according to NLR and PLR, also considering margins status.

Results: NLR >3.9 (hazard ratio [HR] 3.96, P = 0.049), PLR >275 (HR 5.39, P = 0.002) and size on imaging (HR 1.36, P = 0.044) were associated to worse OS. R+ patients with NLR >3.9 showed a significantly lower 5-yr OS compared to NLR ≤3.9 (13.5% vs. 36.7%, P < 0.0001). Also PLR >275 was related with a lower 5-yr OS compared to PLR ≤275 in R+ patients (6.4% vs. 36.8%, P = 0.0003). Conversely, NLR and PLR were irrelevant in case of R0 surgery.

Conclusion: NLR and PLR predict 5-yr OS in LRRC, also identifying a subset of R+ patients with a similar expected survival compared to R0 cases.

Keywords: Locally recurrent rectal cancer; Neoadjuvant therapy; Neutrophil-to-lymphocyte ratio; Overall survival; Platelet-to-lymphocyte ratio.

MeSH terms

  • Blood Platelets
  • Humans
  • Lymphocytes
  • Margins of Excision
  • Neoplasm Recurrence, Local
  • Neutrophils*
  • Prognosis
  • Rectal Neoplasms*
  • Retrospective Studies